Ernexa Therapeutics Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Ernexa Therapeutics Inc. (ERNA) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$4.18 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2016-03-15
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2015-12-31 was -$1.88M.
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2015-09-30 was -$1.09M.
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2015-06-30 was -$2.21M.
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2015-03-31 was $995.00K.
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$4.18M.
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$6.38M, a 466.74% decline from fiscal 2013.
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2013 was $1.74M, a 19.25% decline from fiscal 2012.
- Ernexa Therapeutics Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2012 was $2.16M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|
| 2015-12-31 | -$1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$2.96M derived: sum of 2 quarters · filed 2016-03-15 | -$5.17M derived: sum of 3 quarters · filed 2016-03-15 | -$4.18M 10-K · filed 2016-03-15 | ||
| 2015-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$3.30M derived: sum of 2 quarters · filed 2015-11-09 | -$2.30M 10-Q · filed 2015-11-09 | -$5.25M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2015-06-30 | -$2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$1.22M 10-Q · filed 2015-08-10 | -$4.17M derived: sum of 3 quarters · filed 2016-03-15 | -$5.61M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2015-03-31 | $995.00K 10-Q · filed 2015-05-08 | -$1.95M derived: sum of 2 quarters · filed 2016-03-15 | -$3.40M derived: sum of 3 quarters · filed 2016-03-15 | -$4.94M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-12-31 | -$2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$4.39M derived: sum of 2 quarters · filed 2016-03-15 | -$5.93M derived: sum of 3 quarters · filed 2016-03-15 | -$6.38M 10-K · filed 2016-03-15 | ||
| 2014-09-30 | -$1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$2.98M derived: sum of 2 quarters · filed 2015-11-09 | -$3.44M 10-Q · filed 2015-11-09 | -$2.67M derived: sum of 4 quarters · filed 2015-11-09 | ||
| 2014-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$1.99M 10-Q · filed 2015-08-10 | -$1.22M derived: sum of 3 quarters · filed 2015-08-10 | -$560.00K derived: sum of 4 quarters · filed 2015-08-10 | ||
| 2014-03-31 | -$453.00K 10-Q · filed 2015-05-08 | -$204.00K 10-Q · filed 2014-05-15 | $316.00K derived: sum of 2 quarters · filed 2015-05-08 | $977.00K derived: sum of 3 quarters · filed 2015-05-08 | $1.12M derived: sum of 4 quarters · filed 2015-05-08 | |
| 2013-12-31 | $769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $1.43M derived: sum of 2 quarters · filed 2015-03-27 | $1.57M derived: sum of 3 quarters · filed 2015-03-27 | $1.74M 10-K · filed 2015-03-27 | $1.49M 10-K · filed 2014-03-31 | |
| 2013-09-30 | $661.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $806.00K derived: sum of 2 quarters · filed 2014-11-07 | $972.00K 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $311.00K 10-Q · filed 2014-08-14 | ||||
| 2013-03-31 | $166.00K 10-Q · filed 2014-05-15 | |||||
| 2012-12-31 | $2.16M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |